Literature DB >> 16055230

Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease.

Daniel T Smith1, Riyi Shi, Richard B Borgens, Jennifer M McBride, Kevin Jackson, Stephen R Byrn.   

Abstract

The amine position of the K+ channel blocker 4-aminopyridine was functionalized to form amide, carbamate and urea derivatives in an attempt to identify novel compounds which restore conduction in injured spinal cord. Eight derivatives were tested in vitro, using a double sucrose gap chamber, for the ability to restore conduction in isolated, injured guinea pig spinal cord. The methyl, ethyl and t-butyl carbamates of 4-aminopyridine induced an increase in the post injury compound action potential. The methyl and ethyl carbamates were further tested in an in vivo model of spinal cord injury. These results represent the first time that 4-aminopyridine has been derivatized without losing its ability to restore function in injured spinal cord tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055230     DOI: 10.1016/j.ejmech.2005.04.017

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

Review 1.  Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.

Authors:  Riyi Shi; Wenjing Sun
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

2.  Parallel Evaluation of Two Potassium Channel Blockers in Restoring Conduction in Mechanical Spinal Cord Injury in Rat.

Authors:  Jessica C Page; Jonghyuck Park; Zhe Chen; Peng Cao; Riyi Shi
Journal:  J Neurotrauma       Date:  2018-03-13       Impact factor: 5.269

3.  Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

Authors:  Joseph S Zakhari; Isao Kinoyama; Mark S Hixon; Antonia Di Mola; Daniel Globisch; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2011-09-14       Impact factor: 3.641

4.  The symptomatic management of multiple sclerosis.

Authors:  Randall T Schapiro
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

5.  4-Amino-2,3,5-trimethyl-pyridine monohydrate.

Authors:  Li-Yan Dai; Fu-Liang Zhang; Liang Shen; Ying-Qi Chen
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-05-20

6.  Acrolein-mediated conduction loss is partially restored by K⁺ channel blockers.

Authors:  Rui Yan; Jessica C Page; Riyi Shi
Journal:  J Neurophysiol       Date:  2015-11-18       Impact factor: 2.714

7.  Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.

Authors:  Ji-Hey Lim; Audrey C Muguet-Chanoit; Daniel T Smith; Eric Laber; Natasha J Olby
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

8.  Transdermal delivery of 4-aminopyridine accelerates motor functional recovery and improves nerve morphology following sciatic nerve crush injury in mice.

Authors:  Andrew R Clark; Chia George Hsu; M A Hassan Talukder; Mark Noble; John C Elfar
Journal:  Neural Regen Res       Date:  2020-01       Impact factor: 5.135

9.  Molecular docking study of the binding of aminopyridines within the K+ channel.

Authors:  Norma Angélica Caballero; Francisco Javier Meléndez; Alfonso Niño; Camelia Muñoz-Caro
Journal:  J Mol Model       Date:  2007-03-06       Impact factor: 2.172

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.